Predicting risk of major adverse cardiac events
First Claim
Patent Images
1. A method for evaluating a subject'"'"'s risk of a major adverse cardiac event (MACE) within one year, the method comprising:
- determining a first level of soluble Growth Stimulation-Expressed Gene 2 (ST2) in a biological sample obtained from a subject at a first time point (ST2T0), a second level of soluble ST2 in a biological sample obtained from a subject at a second time point (ST2T1), and a level of natriuretic peptide (NP) in a biological sample obtained from a subject at the second time point (NPT1);
determining a MACE risk score (MACERS) for a subject utilizing, at least in part, a ratio of ST2T1 to ST2T0, in combination with a weighted logarithm of NPT1, andcomparing the MACERS to a reference MACERS;
wherein the MACERS in comparison with the reference MACERS is indicative of the subject'"'"'s risk of a MACE within one year.
2 Assignments
0 Petitions
Accused Products
Abstract
Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.
-
Citations
18 Claims
-
1. A method for evaluating a subject'"'"'s risk of a major adverse cardiac event (MACE) within one year, the method comprising:
-
determining a first level of soluble Growth Stimulation-Expressed Gene 2 (ST2) in a biological sample obtained from a subject at a first time point (ST2T0), a second level of soluble ST2 in a biological sample obtained from a subject at a second time point (ST2T1), and a level of natriuretic peptide (NP) in a biological sample obtained from a subject at the second time point (NPT1); determining a MACE risk score (MACERS) for a subject utilizing, at least in part, a ratio of ST2T1 to ST2T0, in combination with a weighted logarithm of NPT1, and comparing the MACERS to a reference MACERS; wherein the MACERS in comparison with the reference MACERS is indicative of the subject'"'"'s risk of a MACE within one year. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
Specification